The granting of new patents for CM-101 in Brazil and Israel is a significant positive development for Chemomab, indicating a strong proprietary position in these markets. This news could positively influence investor sentiment, as it not only validates the company's research but also potentially secures its commercial position in the future. Given the current stage of clinical development and the anticipation of Phase 2 trial results, this news is likely to be seen as a positive indicator of progress and potential, leading to a short-term positive impact on the stock price.